Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-11-25 am EST
10954.00 GBX   +0.27%
11/25Hopes for Black Friday Boost to Economy Nudge European Equities Higher
MT
11/22AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022
AQ
11/22AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BenevolentAI - Interim results for the six months ended 30 June 2022

09/27/2022 | 10:00am EST

London - BenevolentAI (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited interim results for the six months ended 30 June 2022.

Joanna Shields, Chief Executive Officer of BenevolentAI, said: 'We are pleased with our performance for the first six months of 2022 as we continue to build both internal and external validation of the Benevolent Platform, our AI-enabled drug discovery platform. We progressed our in-house pipeline to 13 named platform-generated drug programmes and over 10 exploratory stage programmes and consistently delivered in our collaboration with AstraZeneca, who expanded the collaboration into two new disease areas and selected an additional target during the period. In May, we also gained further clinical validation of our approach after the FDA issued a full approval of baricitinib, the COVID-19 treatment first identified by BenevolentAI.'

'The capital raised from the business combination and listing in April this year puts us in a solid financial position to progress our development portfolio through near and medium-term key value infection points and allows us to increase investment in our differentiated technology. As we look to the future, BenevolentAI's scalable platform and industry-leading novel target identification capabilities have the potential to transform drug discovery by radically improving our understanding of disease biology and ultimately increasing the probability of clinical success.'

Contact:

Tel: +44(0) 203 781 9360

About BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Forward-looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as 'plans', 'targets', 'aims', 'believes', 'expects', 'anticipates', 'intends', 'estimates', 'will', 'may', 'should' and similar expressions. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; economic outlook and industry trends; developments in BenevolentAI's markets; the impact of regulatory initiatives and/or the strength of BenevolentAI's competitors. These forward-looking statements refiect, at the time made, BenevolentAI's beliefs, intentions and current targets/aims. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this release are based upon various assumptions based on, without limitation, management's examination of historical operating trends, data contained in BenevolentAI's records, and third-party data. Although BenevolentAI believes these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond BenevolentAI's control. Forward-looking statements are not guarantees of future performance, and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of BenevolentAI or the industry to differ materially from those results expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. No representation or warranty is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.27% 10954 Delayed Quote.26.23%
BENEVOLENTAI 2.04% 4 Real-time Quote.-59.70%
All news about ASTRAZENECA PLC
11/25Hopes for Black Friday Boost to Economy Nudge European Equities Higher
MT
11/22AstraZeneca aims to redefine breast cancer care with new data across the treatment spe..
AQ
11/22AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spec..
BU
11/21 Allergy Therapeutics hires interim CFO as Nick Wykeman steps down
AN
11/21Macron hosts European CEOs to counter US move temptation
RE
11/21FTSE 100 eases as China COVID surge knocks energy, mining stocks
RE
11/21Medivir Appoints Former AstraZeneca VP As Chief Medical Officer
MT
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Big Pharma may have to reveal government deals in WHO's draft pandemic rules
RE
11/17Fitch Lifts AstraZeneca's Ratings on Improved Financial Metrics
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 442 M - -
Net income 2022 4 087 M - -
Net Debt 2022 23 636 M - -
P/E ratio 2022 47,4x
Yield 2022 2,23%
Capitalization 205 B 205 B -
EV / Sales 2022 5,15x
EV / Sales 2023 4,82x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,41 $
Average target price 144,66 $
Spread / Average Target 9,26%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC26.23%205 164
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555